This study aimed to retrospectively evaluate the incidence of kerato-conjunctivitis in patients receiving TBI followed by high-dose cytarabine, and to clarify how effectively topical corticosteroid eye drops prevent kerato-conjunctivitis in these patients. Fifty-three patients who received cytarabine at a dose of 3 g/m 2 every 12 h for 4 days after receiving TBI (12 Gy) as a conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) were evaluated. For the prophylaxis of kerato-conjunctivitis, all patients received betamethasone sodium phosphate eye drops every 6 h, starting 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine or the complete resolution of ocular symptoms. For grading of kerato-conjuncitivitis, the National Cancer Institute-Common Toxicity Criteria were used. Among the 53 patients, the grades of kerato-conjunctivitis were grade 0 in 13 patients, grade 1 in 6 patients (11.3%), grade 2 in 10 patients (18.9%) and grade 3 in 25 patients (47.2%). These results strongly suggest that topical corticosteroid eye drops could not effectively prevent the development of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI. Further investigation into a more effective prophylaxis for cytarabine-induced kerato-conjunctivitis in this setting is required.
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Introduction
High-dose cytarabine is important in treatment strategies for AML and ALL. 1 Among its toxicities, an ocular surface toxicity, kerato-conjunctivitis, causes ocular pain, tearing, foreign body sensation, blurred vision and photophobia. 2 It has been reported that corticosteroid eye drops significantly reduce kerato-conjunctivitis due to high-dose cytarabine in the majority of patients, although not completely. 1, 3 In the setting of hematopoietic stem cell transplantation (HSCT), particularly in allogeneic HSCT, high-dose cytarabine is generally used in combination with TBI and/or other chemotherapeutic agents such as CY. [4] [5] [6] [7] [8] [9] In contrast to a non-HSCT setting, this kerato-conjunctivitis has not been described as a clinically significant toxicity or has been disregarded as a minor toxicity in HSCT recipients. We have evaluated and reported the efficacy and safety of a conditioning regimen consisting of TBI and high-dose cytarabine for allogeneic HSCT. 8, 9 In the present study, we retrospectively evaluated the incidence of kerato-conjunctivitis in these patients to clarify the additional effect of TBI on the development of cytarabine-induced kerato-conjunctivitis and the prophylactic effect of a topical corticosteroid.
Patients and methods
Patients and treatment procedure Fifty-three patients with hematologic malignancies, who underwent allogeneic HSCT at Keio University Hospital with a conditioning regimen consisting of TBI and highdose cytarabine as described below, were evaluated. All patient characteristics are shown in Table 1 . After receiving 12 Gy of TBI in 6 doses (2 Gy Â 2 for 3 days), patients received cytarabine at a dose of 3 g/m 2 every 12 h for 4 days as previously reported. 8, 9 For the prophylaxis for kerato-conjunctivitis, all patients received 0.1% betamethasone sodium phosphate eye drops with artificial tears or 0.1% sodium hyaluronate every 6 h, starting 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine (6 days) or complete resolution of any ocular symptoms.
Grading of kerato-conjunctivitis
For grading of kerato-conjuncitivitis, the National Cancer Institute-Common Toxicity Criteria version 2.0 were used. Grading of keratitis and/or conjunctivitis is as follows: grade 0, none; grade 1, ophthalmologic changes, but asymptomatic or symptomatic without visual impairment (that is, pain and irritation); grade 2, symptomatic and interfering with function, but not interfering with activities of daily living; grade 3, symptomatic and interfering with activities of daily living and grade 4 (for keratitis only), unilateral or bilateral loss of vision (blindness). The graded degree of kerato-conjunctivitis was evaluated from medical charts on a daily basis beginning from the first day of high-dose cytarabine until 10 days after the last dose of cytarabine or the complete resolution of kerato-conjunctivitis. The maximum grade of each patient was determined as his or her grade.
Results
Among the 53 patients, the grades of kerato-conjunctivitis were grade 0 in 12 patients, grade 1 in 6 patients (11.3%), grade 2 in 10 patients (18.9%) and grade 3 in 25 patients (47.2%). The overall incidence of clinically significant grade 2-3 kerato-conjunctivitis was 66%. The median duration of grades 2-3 kerato-conjunctivitis was 3 days (range, 1-6 days). No patients developed permanent visual dysfunction due to kerato-conjunctivitis. In contrast, kerato-conjunctivitis was not observed in any of the 28 patients who received cytarabine 2 (instead of 3) g/m 2 every 12 h for 2 (instead of 4) days, which was administered after the same TBI schedule and dosage, and before i.v. CY 120 mg/kg over 2 days. All the 28 patients also received 0.1% betamethasone sodium phosphate eye drops, starting from 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine (4 days).
Discussion
Without topical corticosteroid therapy, the incidence of kerato-conjunctivitis due to high-dose cytarabine is reportedly 85-92%. [1] [2] [3] This frequent and debilitating toxicity can be prevented effectively by topical corticosteroid eye drops, which has been reported to reduce the incidence of clinically significant kerato-conjunctivitis to about 8-16%. 1, 3 In the setting of HSCT, the reported incidence of keratoconjunctivitis due to high-dose cytarabine in combination with TBI is 45-75%, although most reports have not mentioned the incidence of kerato-conjunctivitis, much less prophylactic measures against kerato-conjunctivitis. [4] [5] [6] [7] In accordance with these reports, the results of our study indicated that the patients who received high-dose cytarabine and TBI frequently develop moderate to severe kerato-conjunctivitis (66%). Of note is that during highdose cytarabine therapy, all our patients received topical corticosteroid every 6 h, which has been reported to effectively prevent cytarabine-induced kerato-conjunctivitis. 1, 3 Therefore, it is strongly suggested that topical corticosteroid eye drops are not as effective in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and TBI as in those receiving high-dose cytarabine without TBI.
Local radiotherapy to eyes for ocular malignancies is well known to cause corneal damage, mostly observed after high-dose local radiation therapy administered in multiple fractions. 10, 11 In spite of lower doses, TBI delivered before high-dose cytarabine might have affected the ocular toxicity of cytarabine, and further reduced the prophylactic efficacy of topical corticosteroid.
Besides topical corticosteroid therapy, the efficacy of topical 2-deoxycytidine has been shown to reduce the corneal toxicity of cytarabine as effectively as topical corticosteroid eye drops in a controlled randomized study. 12 Although the result is promising, a preparation of topical 2-deoxycytidine is not commercially available. Another promising prophylaxis is frequent and vigorous application of eye drops with artificial tears (two drops, every 4 h), which was also shown as effective as topical corticosteroid in preventing cytarabine-induced corneal toxicity. 13 The possible mechanism for this frequent and vigorous application of eye drops in preventing cytarabineinduced ocular toxicity is the dilution of cytarabine excreted onto the surface of eyes. 13 Another possible explanation for the reduced efficacy of topical corticosteroid in preventing kerato-conjunctivitis observed in the present study is the difference in the topical corticosteroid used (0.1% betamethasone) as compared with those in other studies (1% prednisolone or 0.1% dexamethasone). 1, 3, 12, 13 Further, the frequency of administration differs among the studies. Therefore, using different glucocorticoid or more frequent administration could contribute to decrease cytarabine-induced ocular toxicity.
It is reported that cytarabine causes kerato-conjunctivitis depending on the dose and duration of the therapy. 2 In contrast to patients receiving cytarabine at a dose of 3 g/m 2 every 12 h for 4 days, kerato-conjunctivitis was not observed in any of the 28 patients who received cytarabine at a dose of 2 g/m 2 every 12 h for 2 days with topical Stem cell source BM/PBSC from related donor 25/6 BM from unrelated donor 22
Kerato-conjunctivitis due to high-dose cytarabine after HSCT T Mori et al corticosteroid eye drops with the same dose of TBI and CY. This finding strongly suggests that, if patients receive topical corticosteroid eye drops, 2-day high-dose cytarabine does not frequently result in kerato-conjunctivitis even in combination with TBI.
In conclusion, transplant physicians should recognize the limited efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis if HSCT recipients serially receive high-dose cytarabine and TBI. Further investigation into a more effective prophylaxis for cytarabine-induced kerato-conjunctivitis in HSCT recipients is clearly warranted.
